![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Ferring Pharmaceuticals |
---|---|
Information provided by: | Ferring Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00329693 |
Women included in this study are undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART) and present with signs of moderate risk of developing OHSS.
Condition | Intervention | Phase |
---|---|---|
Ovarian Hyperstimulation Syndrome |
Drug: Norprolac |
Phase II |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double Blind (Subject, Caregiver), Placebo Control, Parallel Assignment |
Official Title: | A Randomised, Double-Blind, Parallel Groups, Dose-Finding, Placebo-Controlled, Multi-Centre, Proof of Concept Study Assessing the Effect of 3-wk Treatment With 1 of 3 Oral Doses of Quinagolide & Placebo in Preventing Ovarian Hyperstimulation Syndrome in Women Undergoing Controlled Ovarian Hyperstimulation. |
Enrollment: | 182 |
Study Start Date: | June 2006 |
Study Completion Date: | May 2008 |
Primary Completion Date: | August 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Placebo Comparator
Daily Tablets Dosing
|
Drug: Norprolac
Placebo
|
2: Experimental
Daily Tablets Dose
|
Drug: Norprolac
Quinagolide
|
3: Experimental
Daily Tablets Dosing
|
Drug: Norprolac
Quinagolide
|
4: Experimental
Daily Tablets Dosing
|
Drug: Norprolac
Quinagolide
|
No data to be entered.
Ages Eligible for Study: | 21 Years to 37 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Spain | |
IVI Barcelona, Ronda General Mitre, 14 | |
Barcelona, Spain, 08017 | |
IVI Bilbao, Paseo Landabarri, 1 | |
Leioa-Bizkaia, Spain, 48940 | |
IVI Madrid, Santiago de Compostela, 88 | |
Madrid, Spain, 28035 | |
IVI Vigo, Plaza Francisco Fernández del Riego, 7 (Plaza Elíptica) | |
Vigo (Pontevedra), Spain, 36203 | |
IVI Sevilla, Avda. República Argentina, 58 | |
Sevilla, Spain, 41011 | |
IVI Valencia, Plaza de la Policía Local, 3 | |
Valencia, Spain, 46015 | |
IVI Murcia, Navegante Macías del Poyo, 5, Edificio Delfín-Barrio La Flota | |
Murcia, Spain, 30007 |
Study Director: | Clinical Development Support | Ferring Pharmaceuticals |
Responsible Party: | Ferring Pharmaceuticals ( Hjort, Director ) |
Study ID Numbers: | FE 999051 CS01 |
Study First Received: | May 23, 2006 |
Last Updated: | February 17, 2009 |
ClinicalTrials.gov Identifier: | NCT00329693 History of Changes |
Health Authority: | Spain: Ministry of Health |
Genital Diseases, Female Signs and Symptoms Neurotransmitter Agents Dopamine Quinagolide Gonadal Disorders |
Ovarian Hyperstimulation Syndrome Endocrine System Diseases Dopamine Agents Endocrinopathy Ovarian Diseases Dopamine Agonists |
Neurotransmitter Agents Disease Quinagolide Molecular Mechanisms of Pharmacological Action Gonadal Disorders Physiological Effects of Drugs Endocrine System Diseases Ovarian Diseases |
Dopamine Agonists Pharmacologic Actions Adnexal Diseases Genital Diseases, Female Pathologic Processes Syndrome Ovarian Hyperstimulation Syndrome Dopamine Agents |